#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Angiosarcoma non-metastatic Lymphoma Inclusion body myositis Hyperinsulinism Thrombotic thrombocytopenic purpura Thymic carcinoma Cold type haemolytic anaemia Anti-glomerular basement membrane disease Selective polysaccharide antibody deficiency Hydrocephalus Skin angiosarcoma Sarcoidosis Waldenstrom's macroglobulinaemia Squamous cell carcinoma of the oral cavity Nephropathy More trials…

    Learn about Rare Diseases

    Cytokine release syndrome – Trials in Disease Richter’s syndrome – Treatment Mantle cell lymphoma refractory – Life with Disease Osteosarcoma recurrent – Trials in Disease VEXAS syndrome – Diagnostics Hereditary angioedema Marginal zone lymphoma refractory – Trials in Disease Angelman’s syndrome – Basic Information Behcet’s syndrome – Trials in Disease Gaucher’s disease type III More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Magnesium Chloride Gs-1427 Rifaximin Db-Oto-5 Pf-07220060 Monohydrate Glucocorticoids Betula Verrucosa (108) Ropivacaine Gsk4532990A HYDROGEN PEROXIDE Ro7589655 Ocrelizumab Bbp-398 INOBRODIB DUVELISIB Vancomycin Tamoxifen Citrate Tafasitamab Arachis Hypogaea Flour Rezafungin Acetate More therapies…

    Learn about Your Condition

    Lung transplant Iron overload Dyslipidaemia Systemic scleroderma Ewing's sarcoma recurrent Pouchitis Metabolic syndrome Chronic granulomatous disease Abdominal infection Alveolar bone defect Colorectal cancer stage III Infertility Cardiogenic shock Cachexia PIK3CA-activated mutation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

    Recruiting

    2 1
    Investigated Diseases:
    • Persistent corneal epithelial defect
    Investigated Drugs:
    • Lufepirsen
    France Germany Italy Spain

  • Study on Golcadomide for Patients with Relapsed or Refractory Aggressive Large B-Cell Lymphoma at High Risk of Relapse After CAR T-Cell Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Golcadomide
    • Axicabtagene Ciloleucel
    • Tisagenlecleucel
    France

  • Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • 2-((S)-4-((S)-7-(3-Amino-2-Fluoro-5-Methyl-6-(Trifluoromethyl)Phenyl)-2-(((2R,7As)-2-Fluorotetrahydro-1H-Pyrrolizin-7A(5H)-Yl)Methoxy)-7,8-Dihydro-5H-Pyrano(4,3-D)Pyrimidin-4-Yl)-1-(2-Fluoroacryloyl)Piperazin-2-Yl)Acetonitrile
    • Carboplatin
    • Cetuximab
    France Germany Italy Spain

  • Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Tuvusertib
    • Fulvestrant
    France

  • Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Eptinezumab
    Italy Poland Portugal Spain

  • Study of EXL-01 and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immunotherapy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Exl01
    • Nivolumab
    France
Previous Page
1 … 462 463 464 465 466 … 1,653
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!